Literature DB >> 17439730

Affinity of anticancer drug, daunomycin, to core histones in solution: comparison of free and cross-linked proteins.

Azra Rabbani1, Sayeh Abdosamadi, Naghmeh Sari-Saraf.   

Abstract

AIM: The interaction of anthracycline anticancer drugs with chromatin, nucleosomes and histone H1 has been extensively studied. In the present study, for the first time, we have investigated the binding of anthracycline antibiotic, daunomycin, to free and cross-linked thymus core histones (CL-core) in solution and in the absence of DNA.
METHODS: Fluorescence, UV/Vis spectroscopy and equilibrium dialysis techniques were used.
RESULTS: The UV spectroscopy results show that daunomycin induces hypochromicity in the absorption spectra of the core histones. Fluorescence emission intensity is decreased upon daunomycin binding and the process is concentration dependent. The equilibrium dialysis shows that the binding is positive cooperative with the binding sites as Scatchard plot and Hill Coefficient confirm it.
CONCLUSION: The results suggest that daunomycin shows much higher affinity to core histones free in solution than to CL-core, implying that the binding is most likely due to the accessibility of these proteins to the environment. It is suggested that daunomycin binds strongly to open state of histones, such as in tumor cells, rather than to their compact structure seen in normal chromatin.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17439730     DOI: 10.1111/j.1745-7254.2007.00542.x

Source DB:  PubMed          Journal:  Acta Pharmacol Sin        ISSN: 1671-4083            Impact factor:   6.150


  4 in total

1.  Relative binding affinities of integrin antagonists by equilibrium dialysis and liquid chromatography-mass spectrometry.

Authors:  William J Tipping; Nkazimulo Tshuma; James Adams; Harvey T Haywood; James E Rowedder; M Jonathan Fray; Thomas McInally; Simon J F Macdonald; Neil J Oldham
Journal:  ACS Med Chem Lett       Date:  2014-12-22       Impact factor: 4.345

2.  Daunomycin, an antitumor DNA intercalator, influences histone-DNA interactions.

Authors:  Krzysztof Wójcik; Mirosław Zarębski; Andrea Cossarizza; Jurek W Dobrucki
Journal:  Cancer Biol Ther       Date:  2013-06-14       Impact factor: 4.742

3.  The effect of mitoxantrone as an anticancer drug on hepatocytes nuclei and chromatin: Selective release of histone proteins.

Authors:  Zahra Hajihassan; Azra Rabbani-Chadegani
Journal:  Indian J Pharmacol       Date:  2011-04       Impact factor: 1.200

4.  Studies on the binding affinity of anticancer drug mitoxantrone to chromatin, DNA and histone proteins.

Authors:  Zahra Hajihassan; Azra Rabbani-Chadegani
Journal:  J Biomed Sci       Date:  2009-03-11       Impact factor: 8.410

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.